Histone methyltransferase inhibitors
The present disclosure provides certain compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies such as beta-thalassemia and sickle cell disease. Als...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | English |
Published |
22.02.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present disclosure provides certain compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies such as beta-thalassemia and sickle cell disease. Also provided are pharmaceutical compositions containing such compounds as well as processes and intermediates for preparing such compounds. |
---|---|
Bibliography: | Application Number: US201716076307 |